医学信息
醫學信息
의학신식
MEDICAL INFORMATION
2014年
12期
53-54
,共2页
王旻昕%罗震%吴凡%田德英
王旻昕%囉震%吳凡%田德英
왕민흔%라진%오범%전덕영
肝动脉化疗栓塞术(TACE)%原发性肝癌%生存质量%生存率%甲胎蛋白
肝動脈化療栓塞術(TACE)%原髮性肝癌%生存質量%生存率%甲胎蛋白
간동맥화료전새술(TACE)%원발성간암%생존질량%생존솔%갑태단백
Transcatheter arterial chemoembolization%Hepatocellular carcinoma%Quality of live%Survival rate%Alpha fetal protein
目的观察经导管动脉化疗栓塞术（TACE）治疗原发性肝癌的疗效。方法观察94例原发性肝癌行TACE治疗的患者，随访其生存时间及生存质量，观察治疗前后肿瘤大小变化，分析TACE对于原发性肝癌的治疗效果。结果原发性肝癌患者TACE治疗后1年生存率为48.9%（46/94），2年生存率为24.6%，3年生存率为6.3%。首次TACE治疗后14d，外周血甲胎蛋白（AFP）下降率为49.4%。TACE治疗6个月，患者生活质量Karnofsky Performance Scale（KPS）评分好转率为17.07%，Quality of Life Sale (QOL)评分好转率为26.83%，Visual Analogue Scale (VAS)疼痛评分改善率为35.9%。但对于巨块型肝癌，1年生存率仅为3.2%，且TACE术后3个月，KPS评分恶化率为41.9%，QOL评分恶化率为35.5%。结论TACE用于治疗原发性肝癌可一定程度延长患者生存时间，并改善患者的生存质量，抑制癌细胞活动，但对巨块型肝癌效果有限。
目的觀察經導管動脈化療栓塞術（TACE）治療原髮性肝癌的療效。方法觀察94例原髮性肝癌行TACE治療的患者，隨訪其生存時間及生存質量，觀察治療前後腫瘤大小變化，分析TACE對于原髮性肝癌的治療效果。結果原髮性肝癌患者TACE治療後1年生存率為48.9%（46/94），2年生存率為24.6%，3年生存率為6.3%。首次TACE治療後14d，外週血甲胎蛋白（AFP）下降率為49.4%。TACE治療6箇月，患者生活質量Karnofsky Performance Scale（KPS）評分好轉率為17.07%，Quality of Life Sale (QOL)評分好轉率為26.83%，Visual Analogue Scale (VAS)疼痛評分改善率為35.9%。但對于巨塊型肝癌，1年生存率僅為3.2%，且TACE術後3箇月，KPS評分噁化率為41.9%，QOL評分噁化率為35.5%。結論TACE用于治療原髮性肝癌可一定程度延長患者生存時間，併改善患者的生存質量，抑製癌細胞活動，但對巨塊型肝癌效果有限。
목적관찰경도관동맥화료전새술（TACE）치료원발성간암적료효。방법관찰94례원발성간암행TACE치료적환자，수방기생존시간급생존질량，관찰치료전후종류대소변화，분석TACE대우원발성간암적치료효과。결과원발성간암환자TACE치료후1년생존솔위48.9%（46/94），2년생존솔위24.6%，3년생존솔위6.3%。수차TACE치료후14d，외주혈갑태단백（AFP）하강솔위49.4%。TACE치료6개월，환자생활질량Karnofsky Performance Scale（KPS）평분호전솔위17.07%，Quality of Life Sale (QOL)평분호전솔위26.83%，Visual Analogue Scale (VAS)동통평분개선솔위35.9%。단대우거괴형간암，1년생존솔부위3.2%，차TACE술후3개월，KPS평분악화솔위41.9%，QOL평분악화솔위35.5%。결론TACE용우치료원발성간암가일정정도연장환자생존시간，병개선환자적생존질량，억제암세포활동，단대거괴형간암효과유한。
Objective To observe the curative effect of transcatheter arterial chemoembolization(TACE) treatment for hepatocellular carcinoma (HCC). Methods Observed and fol ow-up visited the quality of live and the survival time, of 94 hepatocellular carcinoma patients that received TACE of 328 person-times, and monitored the change of tumor size before and after the treatment, then analyzed the curative effect of TACE for HCC. Results The surviva rate (SR)of HCC patients,after 1 year treatment of TACE,was 49.4%,and 2 years SR was 24.6%, and 3 years SR was 6.3%. After the first time TACE treatment,49.4% patients' alpha fetal protein (AFP) in peripheral blood were reduce. 6 months after TACE treatment, the patients' survival quality, the Karnofsky Performance Scale (KPS)was 17.07% improved, and Quality of Life Sale (QOL) was 26.83% changed for the bet er, and Visual Analogue Scale (VAS)pain score was 35.9% alleviated. For the massive hepatocellular carcinoma especial y, the 1 year SR was 3.2%, and KPS was 41.9% deteriorate,together with QOL was 35.5%worsen after 3 months of TACE treatment. Conclusion It is useful, to a certain extent, to treat HCC with TACE, for extending the patients survival time, or improving their quality of life, or inhibiting their cancer cells activity. However, to treat massive HCC, TACE just have limited ef ects.
